Showing results (891-900 of 1,842) with videos related to

Sort By:
Pageof 185
ESMO Open|June 2, 2022
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysisG Nader-Marta, D Martins-Branco, E Agostinetto, et al.
ESMO Open|June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer RegistryE Laakmann, I Witzel, T Neunhöffer, et al.
ESMO Open|July 7, 2022
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort studyP Osterlund, S Kinos, P Pfeiffer, et al.
ESMO Open|December 1, 2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerE Van Cutsem, H Hochster, K Shitara, et al.
ESMO Open|June 20, 2022
Factors associated with enrolment in clinical trials among women with early-stage breast cancerD Presti, J Havas, D Soldato, et al.
ESMO Open|July 10, 2022
Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysisG Tomasello, D Gambini, F Petrelli, et al.
ESMO Open|October 11, 2021
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatmentA Grinshpun, Y Rottenberg, I Z Ben-Dov, et al.
ESMO Open|April 10, 2022
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancerM Stares, T E Ding, C Stratton, et al.
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
ESMO Open|September 21, 2018
Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapyWataru Goto, Shinichiro Kashiwagi, Yuka Asano, et al.
Pageof 185